KYG8807B1068
KYG8807B1068
Theravance Biopharma, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 884.18M EUR | -- | -- | -- |
Enterprise Value | 535.09M EUR | -- | -- | -- |
Valuation Multiples | ||||
Trailing P/E | 16.38x | -- | -- | -- |
Forward P/E | 13.36x | -- | -- | -- |
Price to Sales | 8.48x | -- | -- | -- |
Price to Book | 3.05x | -- | -- | -- |
EV/Revenue | 5.13x | -- | -- | -- |
EV/EBITDA | 48.2x | -- | -- | -- |
Price to FCF (P/FCF) | 166.8x | -- | -- | -- |
EV/FCF | 100.94x | -- | -- | -- |
FCF Yield | 0.6% | -- | -- | -- |